Management of bladder cancer

Minerva Urologica e Nefrologica

Volumn 60, Issue 4, 2008, Pages 255-264

  Hegarty, P K ^a   Kamat, A M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cystectomy; Urinary bladder neoplasms; Urinary bladder neoplasms, diagnosis; Urinary bladder neoplasms, therapy

Indexed keywords

NUCLEAR MATRIX PROTEIN 22;

BLADDER CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CYSTECTOMY; ENDOSCOPY; HUMAN; SHORT SURVEY; TUMOR BIOPSY;

BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, PAPILLARY; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; META-ANALYSIS AS TOPIC; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 57649119897     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (45)

1. American Cancer Society. Cancer facts and figures 2007. American Cancer Society. Atlanta; 2007. p. 4-19.
2. Sano H, Saika K. International comparisons of cumulative risk of bladder cancer, from cancer incidence in five continents Vol. VIII. Jpn J Clin Oncol 2006;36;757-8.
3. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S et al Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-9.
4. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108-12.
5. Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Canc Res 2008:14;2075-81.
6. rd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N et 1. al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994:54;784-8.
7. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
8. Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 1995;71:831-5.
9. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998;4:829-34.
10. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer epidemiology, diagnosis, and management. Cancer Pract 2002;10:311-22.
11. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998;4:829-34.
12. Au JL, Badalament KA, Woentjes MG, Young DC, Warner JA, Venema PL et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93:597-604.
13. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette- Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-90.
14. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA et al. Maintenance bacillus Calmette- Guerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124-9.
15. Decobert M, Larue H, Harel F, Meyer F, Fradet Y, Lacombe L. Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough? Cancer 2008;9. [Epub ahead of print]
16. Kamat AK. Intravesical BCG: How much is enough? Cancer 2008;9 [Epub ahead of print].
17. Soloway MS, Lopez AE, Patel J, Lu Y. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 1994;73:1926-31.
18. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989;141:22-9.
19. Parmar MK, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 1989;142:284-8.
20. Pruthi RS, Baldwin N, Bhalani V, Wallen EM. Conservative management of low risk superficial bladder tumors. J Urol 2008;179:87-90.
21. Donat SM, North A, Dalbagni G, Herr HW. Efficacy of office fulguration for recurrent low grade papillary tumours less than 0.5cm. J Urol 2004;171:639.
22. Herr HW, Faulkner JR, Grossman HB, Crawford ED. Pathologic evaluation of radical cystectomy specimens: a cooperative group report. Cancer 2004;100:2470-5.
23. World Health Organization (WHO) Consensus Conference on Bladder Cancer, Hautmann RE, Abol-Enein H, Hafez K, Haro I, Mansson W et al. Urinary diversion. Urology 2007;69(Suppl 1)17-49.
24. Barbieri CE, Lee B, Cookson MS, Bingham J, Clark PE, Smith JA Jr et al. Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol 2007;178:1418-22.
25. Aron M, Colombo JR Jr, Haber GP, Campbell SC, Gill IS. Laparoscopic radical cystectomy. BJU Int 2007;100:455-76.
26. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054patients. J Clin Oncol 2001;19:1666-75.
27. Bochner BH, Montie JE, Lee CT. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am 2003;30:777-89
28. Stein JP, Clark P, Miranda G, Cai J, Groshen S, Skinner DG. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol 2005;173:1163-8.
29. Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 2008;70:456-63.
30. Chung PW, Bristow RG, Milosevic MF, Vi QL, Jewett MA, Warde PR et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 2007;25:303-9.
31. Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007;68:1072-80.
32. Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol;11 [Epub ahead of print].
33. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Ratke AO, Tamboli P et al. Micropapillary bladder cancer: a review of the University of Texas MD Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007;110:62-7.
34. Siefker-Radtke AO, Kamat AM, Grossman HB et al. Prospective evidence supporting the utility of neoadjuvant chemotherapy in small cell urothelial cancer: Preliminary results from a phase II clinical trial at the M. D. Anderson Cancer Center. J Urol 2006;175:399.
35. Bex A, Nieuwenhuijzen JA, Kerst M, Pos F, van Boven H, Meinhardt W et al. Small cell carcinoma of bladder: A single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology 2005;65:295-9.
36. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [published correction appears in N Engl J Med 2003;349:1880]. N Engl J Med 2003;349:859-66.
37. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001;19:89-93.
38. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 2006;175:2058-62.
39. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data. Eur Urol 2005;48:202-6.
40. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989;64:2448-58.
41. von der Maase H, Hansen SW, Roberts JT, Dogliotti I, Oliver T, Moore MJ et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxoruhicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
42. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;117:3173-81.
43. Pajk B, Cufer T, Cervak J, Zakotnik B. First-line chemotherapy with cisplatin, methotrexate and vinblastine in metastatic bladder cancer. Tumori 1996;82:453-5.
44. Loehrer P, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-73.
45. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15:3394-8.